Biote Corp (BTMD)
5.75
-0.09
(-1.54%)
USD |
NASDAQ |
May 17, 16:00
5.86
+0.11
(+1.91%)
After-Hours: 20:00
Biote SG&A Expense (Quarterly): 23.01M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 23.01M |
| December 31, 2023 | 26.19M |
| September 30, 2023 | 23.79M |
| June 30, 2023 | 25.76M |
| March 31, 2023 | 23.08M |
| December 31, 2022 | 21.76M |
| Date | Value |
|---|---|
| September 30, 2022 | 20.82M |
| June 30, 2022 | 113.42M |
| March 31, 2022 | 15.10M |
| December 31, 2021 | 17.64M |
| September 30, 2021 | 13.73M |
| June 30, 2021 | 12.39M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
12.39M
Minimum
Jun 2021
113.42M
Maximum
Jun 2022
28.06M
Average
22.38M
Median
SG&A Expense (Quarterly) Benchmarks
| Teladoc Health Inc | 349.39M |
| American Shared Hospital Services | 1.76M |
| Novo Integrated Sciences Inc | 2.864M |
| Astrana Health Inc | 38.72M |
| Cryo-Cell International Inc | 4.340M |